Details checkedClinical trial listing onlyCheckedregistry

Mass Eye and Ear IV lidocaine fMRI tinnitus study

Also known as: Iv Lidocaine, fMRI IV lidocaine tinnitus study, NCT04192773, 2019P0002539

Investigator-led study

Primary source

Sponsor / Institution

Investigator-led study

Program Type

Diagnostic

Modality

Diagnostic

Stage

Phase 1

Status

Active

Target Gene

—

Route / Mode

Intravenous lidocaine infusion plus fMRI

Confidence

80%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, tinnitus, hearing-loss, normal-hearing-control, neuroimaging

Trial IDs

Mechanism

Open-label pharmacologic fMRI challenge study comparing tinnitus-related brain activity before and after IV lidocaine infusion; the purpose is diagnostic/neuroimaging signal discovery rather than development of a tinnitus drug product.

Indications

Tinnitus Hearing Loss

Notes

Reclassified from a therapeutic pipeline row to a diagnostic/pharmacologic challenge study. ClinicalTrials.gov lists D. Bradley Welling/Mass Eye and Ear as sponsor-investigator context, and the stated primary purpose is diagnostic fMRI network identification after IV lidocaine.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, programType, stage, status, route...

IDs: NCT04192773, 2019P0002539

Open

Key Events

2019-12-10

IV lidocaine fMRI tinnitus study first posted

2025-12-02

ClinicalTrials.gov update lists the study as recruiting

Clinical Trials (1)